1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
Delayed Australian Stock Exchange  -  05/24 01:33:25 am EDT
0.1100 AUD    0.00%
04/25TRANSCRIPT : ResApp Health Limited, Q3 2022 Earnings Call, Apr 26, 2022
CI
04/25RESAPP HEALTH : Quarterly Activities Report and Appendix 4C
PU
04/11Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited for approximately AUD 100 million.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : receives world's first regulatory approvals for cough counter smartphone application

11/29/2021 | 05:01pm EDT

View printer-friendly version

  • Smartphone-only cough counter application approved as a medical device in Australia and Europe
  • Technology already in use by a global pharmaceutical company to monitor disease in a clinical trial
  • Discussions on-going with customers for use in clinical research and monitoring disease progression in patient support and management programs

Brisbane, Australia, 29 November 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that it has achieved Australian Therapeutics Good Administration (TGA) clearance and CE Mark certification for the world's first regulatory-approved standalone cough counter smartphone application. The application is now listed on the Australian Register of Therapeutic Goods (ARTG) and available for sale in Europe as a class I medical device.

ResApp's standalone cough counter application tracks cough frequency using only a smartphone. The application uses ResApp's proprietary machine learning algorithms to accurately identify cough events from audio recorded using the smartphone's in-built microphone.

Cough frequency is a key factor in determining and managing respiratory disease progression and may also be a valuable outcome measure in clinical trials involving a broad range of disease states where cough is implicated. Traditionally, the only ways to measure the cough frequency is by subjective self-reporting or manually listening to audio recordings. These methods are labour intensive, not cost effective and inaccurate. The cough counting application was developed to deliver patients, healthcare providers and researchers more accurate and reliable analysis for disease monitoring.

ResApp's cough counting technology is already being used by the global biopharmaceutical company AstraZeneca to monitor patients participating in a lung cancer clinical trial and an asthma management support program.

CEO and Managing Director, Dr Tony Keating said: "We are pleased to have secured regulatory clearance in Australia and Europe for our cough counting technology. The ability to measure cough frequency using only a smartphone is a highly scalable solution that has a number of broad clinical applications. After our success in partnering with AstraZeneca, we are particularly excited about the opportunity in supporting clinical trials, where cough can provide important insight into the progression of disease and efficacy of treatment."

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Disclaimer

ResApp Health Limited published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 November 2021 22:00:04 UTC.


© Publicnow 2021
All news about RESAPP HEALTH LIMITED
04/25TRANSCRIPT : ResApp Health Limited, Q3 2022 Earnings Call, Apr 26, 2022
CI
04/25RESAPP HEALTH : Quarterly Activities Report and Appendix 4C
PU
04/11Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited for appro..
CI
04/10RESAPP HEALTH : Proposed Acquisition of ResApp Health by Pfizer
PU
04/07TRANSCRIPT : ResApp Health Limited - Special Call
CI
04/01RESAPP HEALTH : Dartford and Gravesham NHS Trust to pilot ResAppDx
PU
03/31ResApp Health Signs Deal for Pilot Testing of Respiratory Diagnostic App in the UK
MT
03/31ResApp Health Limited Signs One Year Agreement with the Dartford and Gravesham National..
CI
03/24Kairos Minerals Ltd - Board Update
AQ
03/22ResApp Health's Cough-based Diagnostic Test Achieves 92% Sensitivity Rate for COVID-19 ..
MT
More news
Financials
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,82 M -4,82 M
Net cash 2021 6,40 M 4,55 M 4,55 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 94,5 M 67,2 M 67,2 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 510
Free-Float 80,9%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED69.23%68
SNAP INC.-52.22%36 768
KAKAO GAMES CORP.-35.38%3 606
ANGI INC.-45.71%2 512
DENA CO., LTD.12.76%1 853
MODERN TIMES GROUP MTG AB (PUBL)21.86%1 261